Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel

By Brian Orelli, PhD – Feb 18, 2020 at 2:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales of the treatment got off to a good start in the U.S., and Europe could follow suit.

The European Commission has officially approved Pfizer's (PFE -0.91%) drug Vyndaqel as a treatment for transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM), a disease characterized by the buildup of misfolded TTR protein in the heart. Vyndaqel is designed to stabilize the protein and keep it from misfolding.

The drug was previously approved at a lower dose for ATTR patients with a buildup of the misfolded protein in their nervous system, but sales of the drug were limited due to relatively lackluster efficacy data for patients with the polyneuropathy version of the disease.

By contrast, the results for ATTR-CM were outstanding. Over the 30 months that patients took the drug, Vyndaqel reduced the risk of death by 30% compared to placebo. It also reduced the frequency of cardiovascular-related hospitalization by 32%.

Doctor listening to a patient's heart with a stethoscope

Image source: Getty Images.

The dose for the ATTR-CM is four times higher than the dose for the polyneuropathy version, so Pfizer developed a single-pill free acid form, which it calls Vyndamax in the U.S., so patients don't have to take four pills every day.

Vyndaqel was launched in the U.S. last May, while Vyndamax was launched in September. Pfizer has been able to ramp up sales relatively quickly; it generated $104 million in combined U.S. sales of Vyndaqel and Vyndamax in the fourth quarter.

The launch in Europe may take longer as the pharmaceutical company will have to negotiate with payers in each country in the EU. There's some indication that the demand for the drug is there; sales in developed Europe doubled year over year in the fourth quarter from $25 million to $53 million, suggesting some doctors have been prescribing the drug off-label before it received official approval.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.